

DAFTAR PUSTAKA

1. Wentzensen N, Poole EM, Trabert B, White E, Arslan AA, Patel AV, et al. Ovarian cancer risk factors by histologic subtype: An analysis from the Ovarian Cancer Cohort Consortium. *J Clin Oncol.* 2016;34(24):2888-2898.
2. Globocan Observatory W. Cancer Today - World. *Int Agency Res Cancer.* 2019;876:9
3. SEER(2018).Cancer Stat Facts: Ovary Cancer. National Cancer Institute. <https://seer.cancer.gov/statfacts/html/ovary.html> - Diakses 1 April 2020
4. World Health Organization. Indonesia source globocan 2018. *Int Agency Res Cancer.* 2019;256:1–2.
5. Widodo J, Wijaya SM, Rudiyanto W. Hubungan faktor risiko (riwayat keluarga, obesitas, dan alat kontrasepsi terhadap derajat histopatologi kanker ovarium di RSUD Dr . H . Abdul Moeloek Bandar Lampung tahun 2018. *J Medula.* 2019;8(2):154-160.
6. Imanuel TG, Maria FL, Freddy WW. Gambaran jenis kanker ovarium di RSUP Prof . Dr . R . D . Kandou Manado. *E-Clinic.* 2016;4(2):2–6.
7. Momenimovahed Z, Tiznobaik A, Taheri S, Salehiniya H. Ovarian cancer in the world: Epidemiology and risk factors. *Int J Womens Health.* 2019;11:287-299.
8. Jung EJ, Eom HM, Byun JM, Kim YN, Lee KB, Sung MS, et al. Different features of the histopathological subtypes of ovarian tumors in pre- and postmenopausal women. *The Journal of the North American Society* 2017;24(9):1028-1032.
9. Doubeni CA, Anna R, Allison EM. Diagnosis and management of ovarian cancer. *American Family Physician.*2016;93(11):940.
10. National Academies of Sciences, Engineering, and Medicine. Ovarian cancers: evolving paradigms in research and care. *The National Academies Press.* 2016;20.
11. Dhitayoni, Ida A, Budiana, I Nyoman G. Profil pasien kanker ovarium di Rumah Sakit Umum Pusat Sanglah Denpasar - Bali periode Juli 2013 - Juni 2014. *E-Jurnal Medika Udayana.*2017;6(3):2.
12. Nersesian S, Glazebrook H, Toulany J, Grantham S R, Boudreau JE. Naturally killing the silent killer: NK cell-based immunotherapy for ovarian cancer. *Frontiers in Immunology.* 2019;10:1.
13. Xu Y, Xu L, Zheng J, Geng L, Zhao S. MiR-101 inhibits ovarian carcinogenesis by repressing the expression of brain-derived neurotrophic factor. *FEBS Open Bio.*2017; 7(9): 1258–1266.
14. Webb PM, Jordan SJ. Epidemiology of epithelial ovarian cancer. *Best Practice & Research Clinical Obstetrics & Gynaecology.*2017; 41:3–14.
15. Siegel RL, Miller KD, Jemal A. Cancer statistics 2020. *CA Cancer J Clin.*2020;70(1):7–30.
16. Berek JS, Hacker NF. Berek & hacker's gynecologic oncology. 6th ed. Philadelphia (PA): Wolters Kluwer; 2015.
17. Waruwu D, Lukito JS. Ekspresi P53 mutan dengan jenis histopatologik dan derajat diferensiasi karsinoma ovarium. 2016;25(2):19–23.
18. Matulonis UA, Sood AK, Fallowfield L, Howitt BE, Sehouli J, Karlan BY. Ovarian cancer. *Nat Rev Dis Prim.*2016;2:1–22.

19. Singer CF, Tan YY, Muhr D, Rappaport C, Gschwantler-Kaulich D, Grimm C, et al. Association between family history, mutation locations, and prevalence of BRCA1 or 2 mutations in ovarian cancer patients. *Cancer Med.* 2019;8(4):81
20. Bareppady S, Nayak S. Relation of menarche, breast and ovarian Cancer in women. *J Heal Allied Sci NU.* 2019;09(02):76–80.
21. Fortner RT, Poole EM, Wentzensen NA, Trabert B, White E, Arslan AA, et al. Ovarian cancer risk factors by tumor aggressiveness: An analysis from the Ovarian Cancer Cohort Consortium. *Int J Cancer.* 2019;145(1):58–69.
22. Sung HK, Ma SH, Choi JY, Hwang Y, Ahn C, Kim BG, et al. The effect of breastfeeding duration and parity on the risk of epithelial ovarian cancer: A systematic review and meta-analysis. *Journal of Preventive Medicine and Public Health.* 2016;49(6):353.
23. Gaitskell K, Green J, Pirie K, Barnes I, Hermon C, Reeves GK, et al. Histological subtypes of ovarian cancer associated with parity and breastfeeding in the prospective Million Women Study. *Int J Cancer.* 2018;142(2):281–289.
24. Modugno F, Goughnour SL, Wallack D, Edwards RP, Odunsi K, Kelley JL, et al. Breastfeeding factors and risk of epithelial ovarian cancer. *Gynecol Oncol.* 2019;153(1):116–122
25. Tworoger SS, Huang T. Obesity and ovarian cancer. *Recent Results Cancer Res.* 2016;208:155–176.
26. Foong KW, Bolton H. Obesity and ovarian cancer risk: A systematic review. *Post Reprod Heal.* 2017;23(4):183–198
27. George SHL, Garcia R, Slomovitz BM. Ovarian cancer: the fallopian tube as the site of origin and opportunities for prevention. *Front Oncol.* 2016;2.
28. Kroeger PT, Drapkin R. Pathogenesis and heterogeneity of ovarian cancer. *Curr Opin Obstet Gynecol.* 2017;29(1):26–34.
29. Arania R, Windarti I. Karakteristik pasien kanker ovarium di rumah sakit Dr .H Abdul Moeloek periode 2009–2013. *Jurnal Kedokteran Unila.* 2015;5:43–47
30. Karst AM, Drapkin R. Ovarian Cancer Pathogenesis: A Model in Evolution. *Journal of Oncology.* 2010:1–13.
31. Lahmuddin T, Maulani H, Musa Z, Saleh I. Korelasi antara overekspresi p53 dengan derajat histopatologi dan stadium klinis karsinoma ovarium. *Jurnal Kedokteran dan Kesehatan.* 2015;2(3):267–275
32. Grisham RN, Iyer G, Garg K, DeLair D, Hyman DM, Zhou Q, et al. BRAF Mutation is associated with early stage disease and improved outcome in patients with low-grade serous ovarian cancer. *Cancer.* 2012;119(3):548–554.
33. Katagiri A, Nakayama K, Rahman MT, et al. Loss of ARID1A expression is related to shorter progression-free survival and chemoresistance in ovarian clear cell carcinoma. *Mod Pathol.* 2012;25(2):282–288.
34. Itamochi H, Kigawa J, Terakawa N. Mechanisms of chemoresistance and poor prognosis in ovarian clear cell carcinoma. *Cancer Sci.* 2008;99(4):653–658.
35. Ebell MH, Culp MB, Radke TJ. A systematic review of symptoms for the

- diagnosis of ovarian cancer. *Am J Prev Med.* 2016;50(3):384-394.
36. Dilley J, Burnell M, Gentry-Maharaj A, Ryan A, Neophytou C, Apostolidou S, et al. Ovarian cancer symptoms, routes to diagnosis and survival - population cohort study in the 'no screen' arm of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). *Gynecol Oncol.* 2020;158(2):316-322.
 37. Biggs WS, Marks ST. Diagnosis and management of adnexal masses. *Am Fam Physician.* 2016;93(8):676-681.
 38. National Institute for Health and Care Excellence. Ovarian cancer : detection in primary care. London NICE. 2021;3.
 39. Malagelada JR, Accarino A, Azpiroz F. Bloating and abdominal distension: old misconceptions and current knowledge. *Am J Gastroenterol.* 2017;112(8):1221-1231.
 40. Aston J, Biscoe E, Tate S. Ovarian cancer in primary care: The role of GPNs. *Practice Nursing.* 2017; 28(10): 444-447.
 41. Martin ML, Halling K, Eek D. Lower abdominal pains, as if I was being squeezed in a clamp: A qualitative analysis of symptoms, patient-perceived side effects and impacts of ovarian cancer. *Patient.* 2020;189-200.
 42. Mari A, Abu Backer F, Mahamid M, Amara H, Carter D, Boltin D, et al. Bloating and abdominal distension: Clinical approach and management. *Adv Ther.* 2019;36(5):1075-1084
 43. Bankhead C, Collins C, Stokes-Lampard H, Rose P, Wilson S, Clements A, et al. Identifying symptoms of ovarian cancer: a qualitative and quantitative study. *BJOG: An International Journal of Obstetrics & Gynaecology.* 2008; 115(8):1008-1014.
 44. Suh-Burgmann EJ, Alavi M. Detection of early stage ovarian cancer in a large community cohort. *Cancer Med.* 2019;8(16):7133-7140.
 45. Goff, B. Symptoms associated with ovarian cancer. *Clinical Obstetrics and Gynecology.* 2012;55(1):36-42.
 46. Barakat, RR. Principles and practice of gynecologic oncology 6th Ed. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins. 2013;771.
 47. Telford B, Condon T, Flynn B, Cassidy J, Feely O, Murphy G, et al. Early satiety in cancer: a clinical review of definition and therapeutic management. *Trinity Student Medical Journal.* 2020;20(1):57-61
 48. Sowerbutts AM, Lal S, Sremanakova J, Clamp AR, Jayson GC, Hardy L, et al. Dealing with loss: food and eating in women with ovarian cancer on parenteral nutrition. *J Hum Nutr Diet.* 2020;1-7.
 49. Barajas Galindo DE, Vidal CA, Calleja FA, Hernández MA, Pintor de la Maza B, Pedraza LM. Appetite disorders in cancer patients: impact on nutritional status and quality of life. *Appetite.* 2017;114:23-27.
 50. Bodean OM, Marcu RD, Spinu DA, Socea B, Diaconu CC, Munteanu O, et al. Pelvic floor disorders in gynecological malignancies. an overlooked problem?. *J Mind Med Sci.* 2018; 5(1): 46-52.
 51. Pizzoferrato AC, Klein M, Fauvet R, Durand C, Foucher F, Sardain H. Pelvic floor disorders and sexuality in women with ovarian cancer: A systematic review. *Gynecologic Oncology.* 2021;161(1):264-274.

52. Vaughan CP, Markland AD. Urinary incontinence in women. *Ann Intern Med.* 2020;172(3):17-32.
53. Ford CE, Werner B, Hacker NF, Warton K. The untapped potential of ascites in ovarian cancer research and treatment. *Br J Cancer.* 2020;123: 9–16
54. Cerne K, Kobal B. Ascites in advanced ovarian cancer. *Intech Open.* 2018;198-210
55. Rudralingam V, Footitt C, Layton B. Ascites matters. *Ultrasound.* 2017;25(2):69-79.
56. Meyer L, Suidan R, Sun C, Westin S, Coleman RL, Mills GB. The management of malignant ascites and impact on quality of life outcomes in women with ovarian cancer. *Expert Rev Qual Life Cancer Care.* 2016;1(3):231-238.
57. Getnet W, Kebede T, Atinafu A, Sultan A. The value of ultrasound in characterizing and determining the etiology of ascites. *Ethiop J Health Sci.* 2019;29(3):383-390.
58. Szkodziak P, Czuczwar P, Pyra K, Szkodziak F, Paszkowski T, Rio TH, et al. Ascites index – an attempt to objectify the assessment of ascites. *J Ultrason.* 2018;18:140–147.
59. Stewart C, Ralyea C, Lockwood S. Ovarian cancer: An integrated review. *Semin Oncol Nurs.* 2019;35(2):154.
60. National Comprehensive Cancer Network. Ovarian cancer. *NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw.* 2019;17(8): 896-909.
61. American College of Obstetricians and Gynecologists Committee on Practice Bulletins - Gynecology. Practice bulletin no. 174: evaluation and management of adnexal masses. *Obstet Gynecol.* 2016;128(5):e210-e226.
62. Arora T, Mullangi S, Lekkala MR (2021). Ovarian cancer. *Stat Pearls Publishing.* Available from ://www.ncbi.nlm.nih.gov/books/NBK567760/- Diakses Juni 2021
63. Kipps E, Tan DS, Kaye SB. Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research. *Nat Rev Cancer.* 2013;13(4):273-282.
64. Orr B, Edwards RP. Diagnosis and treatment of ovarian cancer. *Hematology/Oncology Clinics of North America.* 2018;32(6):944.
65. Solanki V, Singh P, Sharma C, Ghuman N, Sureka B, Shekhar S, et al. Predicting malignancy in adnexal masses by the international ovarian tumor analysis-simple rules. *J Midlife Health.* 2020;11(4):217-223.
66. Nurhayati, Muis M, Ilyas M. Nilai diagnostik ultrasonografi doppler dalam menentukan keganasan tumor ovarium dibandingkan hasil histopatologi. *Mandala Of Health : A Scientific Journal.* 2019;12(2):195-205.
67. Pereira PN, Sarian LO, Yoshida A, Araújo KG, Silva ACB, de Oliveira Barros RH, et al. Improving the performance of IOTA simple rules: sonographic assessment of adnexal masses with resource-effective use of a magnetic resonance scoring (ADNEX MR scoring system). *Abdom Radiol (NY).* 2020;45(10):3218-3229.
68. Yuliati I, Perbowo P, Mulawardhana P, Nugroho H, Indraprasta BR, Harjanto, B, et al. Panduan tatalaksana kanker ginekologi. *Scopinda Media*

Pustaka.2020

69. Ariningtyas ND. CA 125 dan pemakaian klinis dalam penatalaksanaan kanker ovarium. *Qanun Medika*. 2018;2(2):73-81
70. Ledermann JA, Raja FA, Fotopoulou C, Gonzalez-Martin A, Colombo N, Sessa C. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. *Annals of Oncology*. 1 Oktober 2013;24(6):24–32.
71. American Joint Committee on Cancer. Ovary, fallopian tube, and primary peritoneal carcinoma. In: *AJCC Cancer Staging Manual*. 8th ed. New York, NY: Springer. 2017;681-690.
72. Prat J; FIGO Committee on Gynecologic Oncology. Staging classification for cancer of the ovary, fallopian tube, and peritoneum. *Int J Gynecol Obstet*. 2014;124(1):1-5.
73. Meinhold-Heerlein I, Fotopoulou C, Harter P, Kurzeder C, Mustea A, Wimberger P, et al. The new WHO classification of ovarian, fallopian tube, and primary peritoneal cancer and its clinical implications. *Arch Gynecol Obstet*. 2016;293(4):695–700.
74. Romero I, Leskelä S, Mies BP, Velasco AP, Palacios J. Morphological and molecular heterogeneity of epithelial ovarian cancer: Therapeutic implications. *EJC Suppl*. 2020;15:1-15.
75. Kumar V, Abbas A, Aster J. *Robbins basic pathology*. 9th ed. Elsevier Saunders. 2013;686-688
76. Berney DM, Stoneham S, Arora R, Shamash J, Lockeley M. Ovarian germ cell tumour classification: views from the testis. *Histopathology*. 2002;76:25-36
77. Fujin C, Zhongli C, Minshan C, Yingbo C, Zhongping C, Nianji C, et al., editors. *Buku ajar onkologi klinis*. Edisi 2. Jakarta: Badan Penerbit FKUI; 2013.
78. Kim SK, Park JW. A case of malignant fibrothecoma of the ovary. *Korean Journal of Obstetric & Gynecology*. 2012;55(3):187-191
79. Karlan BY, Bristow RE, Andrew JL. *Gynecologic oncology clinical practice and surgical atlas*. New York: McGraw Hill; 2012.
80. Dahlan, Sopiudin M. 2013. *Besar Sampel dan Cara Pengambilan Sampel*. Salemba Medika. 2013.
81. Carvalho J P, Moretti-Marques R, Filho AL. Adnexal mass: diagnosis and management. *Revista Brasileira de Ginecologia e Obstetrícia / RBGO Gynecology and Obstetrics*. 2020; 42(07):438–443.
82. Budiana ING, Prayudi PKA, Saspriyana KY, Darmayasa IM, Wiradnyana AAG, Suwiyoga K. Characteristics of ovarian malignancy in Bali province, Indonesia. *The Medical Journal of Malaysia*. 2021;76(3): 326-331.
83. Charkhchi P, Cybulski C, Gronwald J, Wong FO, Narod SA, Akbari MR. CA125 and ovarian cancer: A comprehensive review. *Cancers (Basel)*. 2020;12(12):3730.
84. Arianto A, Istiadi H, Puspasari D. Profil epithelial ovarian carcinoma (EOC) di Rumah Sakit Umum Dr. Kariadi Semarang. *Zona Kebidanan : Program Studi Kebidanan Universitas Batam*. 2021;11(3):75-80.
85. Gomes TA, Campos EA, Yoshida A, Sarian LO, de Angelo Andrade LAL, Derchain SF. Preoperative differentiation of benign and malignant non-

- epithelial ovarian tumors: clinical features and tumor markers. *Revista Brasileira de Ginecologia e Obstetrícia/RBGO Gynecology and Obstetrics*. 2020;42(09):555-561.
86. Boussios S, Zarkavelis G, Seraj E, Zerdes I, Tatsi K, Pentheroudakis G. Non-epithelial ovarian cancer: elucidating uncommon gynaecological malignancies. *Anticancer research*. 2016;36(10):5031-5042.
 87. Fuh KC, Shin JY, Kapp DS, Brooks RA, Ueda S, Urban RR, et al. Survival differences of Asian and Caucasian epithelial ovarian cancer patients in the United States. *Gynecologic oncology*. 2017;136(3): 491-497.
 88. Himpunan Onkologi Ginekologi Indonesia. *Kanker ovarium*. Kanker Ginekologi. (3rd ed). Jakarta, 2013; p. 89-01.
 89. Risch, Harvey A. Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone. *Journal of the National Cancer Institute*. 1998;90 (23):1774-1786
 90. Nieman KM, Kenny HA, Penicka CV, Ladanyi A, Buell-Gutbrod R, Zillhardt MR, et al. Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. *Nature medicine*. 2011;17(11): 1498-1503.
 91. Olsen CM, Green AC, Whiteman DC, Sadeghi S, Kolahdooz F, Webb PM. Obesity and the risk of epithelial ovarian cancer: a systematic review and meta-analysis. *European journal of cancer*. 2007;43(4):690-709.
 92. Negri E, Pelucchi C, Franceschi S, Montella M, Conti E, Dal Maso L, et al. Family history of cancer and risk of ovarian cancer. *European Journal of Cancer*. 2003;39(4):505-510.
 93. Yanti DA, Sulistianingsih A. Faktor determinan terjadinya kanker ovarium di Rumah Sakit Umum Daerah Abdoel Moelok Provinsi Lampung 2015. *E Journal UMM*. 2016;7(2):79-87
 94. Putri K., Tambunan BA, Sandhika W. Diagnostic value of CA-125 in patients with epithelial ovarian cancer at the Dr. Soetomo General Hospital Surabaya in 2016. *Indonesian Journal of Clinical Pathology and Medical Laboratory*. 2019;25(2):145-149.
 95. Akhavan S, Ghahghaei-Nezamabadi A, Modaresgilani M, Mousavi AS, Sepidarkish M, Tehranian A, et al. Impact of diabetes mellitus on epithelial ovarian cancer survival. *BMC cancer*. 2018;18(1):1-6.
 96. Wang L, Zhong L, Xu B, Chen M, Huang H. Diabetes mellitus and the risk of ovarian cancer: a systematic review and meta-analysis of cohort and case-control studies. *BMJ open*. 2020;10(12):1-10.
 97. Chase DM, Neighbors J, Perhanidis J, Monk BJ. Gastrointestinal symptoms and diagnosis preceding ovarian cancer diagnosis: Effects on treatment allocation and potential diagnostic delay. *Gynecologic Oncology*. 2021;161(3): 832-837.
 98. Pitts MK, Heywood W, Ryall R, Smith AM, Shelley JM, Richters J, et al. High prevalence of symptoms associated with ovarian cancer among Australian women. *Australian and New Zealand Journal of Obstetrics and Gynaecology*. 2011;51(1):71-78.
 99. Lurie G, Thompson PJ, McDuffie KE, Carney ME, Goodman MT. Prediagnostic symptoms of ovarian carcinoma: a case-control study. *Gynecologic oncology*. 2009;114(2):231-236.

100. Lataifeh I, Marsden DE, Robertson G, Gebski V, Hacker NF. Presenting symptoms of epithelial ovarian cancer. *Australian and New Zealand Journal of Obstetrics and Gynaecology*. 2005; 45(3):211-214.
101. Elshami M, Yaseen A, Alser M, Al-Slaibi I, Jabr H, Ubaiat S, et al. Knowledge of ovarian cancer symptoms among women in Palestine: a national cross-sectional study. *BMC Public Health*. 2021;21(1):1-10.
102. Huepenbecker SP, Sun CC, Fu S, Zhao H, Primm K, Giordano SH, et al. Factors impacting the time to ovarian cancer diagnosis based on classic symptom presentation in the United States. *Cancer*. 2021;127(22):4151-4160.
103. Rossing MA, Wicklund KG, Cushing-Haugen KL, Weiss NS. Predictive value of symptoms for early detection of ovarian cancer. *Journal of the National Cancer Institute*. 2010;102(4):222-229.
104. Berek JS, Bast Jr RC. Epithelial ovarian cancer. In *Holland-Frei Cancer Medicine*. 6th edition. BCAS Decker. 2003. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK13342/>. Diakses 10 Oktober 2022
105. Yawn BP, Barrette BA, Wollan PC. Ovarian cancer: the neglected diagnosis. *Mayo Clinic Proceedings*. 2004;79(10):1277-1282.
106. Matsuo K, Ahn EH, Prather CP, Eno ML, Im DD, Rosenshein NB. Patient-reported symptoms and survival in ovarian cancer. *International Journal of Gynecologic Cancer*. 2011;21(9).
107. Ayhan A, Gultekin M, Taskiran C, Dursun P, Firat P, Bozdog G, et al. Ascites and epithelial ovarian cancers: a reappraisal with respect to different aspects. *International Journal of Gynecologic Cancer*. 2007;17(1).
108. Huang H, Li YJ, Lan CY, Huang QD, Feng YL, Huang YW, Liu JH. Clinical significance of ascites in epithelial ovarian cancer. *Neoplasma*. 2013;60(5):546-552.
109. Krugmann J, Schwarz CL, Melcher B, Sterlacci W, Ozalinskaite A, Lermann J, et al. Malignant ascites occurs most often in patients with high-grade serous papillary ovarian cancer at initial diagnosis: A retrospective analysis of 191 women treated at Bayreuth Hospital, 2006–2015. *Archives of gynecology and obstetrics*. 2019;299(2): 515-523.
110. Shen Y, Liang Y, Cheng X, Lu W, Xie X, Wan X. Ovarian fibroma/fibrothecoma with elevated serum CA125 level: A cohort of 66 cases. *Medicine (Baltimore)* 2018; 97 (34) e11926
111. Akazawa M, Hashimoto K. Artificial intelligence in ovarian cancer diagnosis. *Anticancer research*. 2020;40(8):4795-4800.
112. Horvath LE, Werner T, Boucher K, Jones K. The relationship between tumor size and stage in early versus advanced ovarian cancer. *Medical hypotheses*. 2013;80(5):684-687.
113. Gupta N, Yadav M, Gupta V, Chaudhary D, Patne SC. Distribution of various histopathological types of ovarian tumors: A study of 212 cases from a tertiary care center of Eastern Uttar Pradesh. *Journal of Laboratory Physicians*. 2019;11(01): 075-081.
114. Kumar N, Yadav A, Kaur H. Histopathological Variants of Ovarian Tumors and Their Presentation in Rural Tertiary Care Center of Northern India: An Observational Study. *Indian Journal of Gynecologic Oncology*.

- 2020;18(1):1-8.
115. Malik YA, Friadi A. ROMA and IOTA Score Comparison in Predicting Ovarian Tumour Malignancy. *Andalas Obstetrics And Gynecology Journal*. 2020;4(1):70-76.
 116. Garg S, Kaur A, Mohi JK, Sibia PK, Kaur N. Evaluation of IOTA simple ultrasound rules to distinguish benign and malignant ovarian tumours. *Journal of Clinical and Diagnostic Research: JCDR*. 2017;11(8):06.
 117. Xie WT, Wang YQ, Xiang ZS, Du ZS, Huang SX, Chen YJ, et al. Efficacy of IOTA simple rules, O-RADS, and CA125 to distinguish benign and malignant adnexal masses. *Journal of ovarian research*. 2022;15(1):15.
 118. Van Calster B, Valentin L, Van Holsbeke C, Zhang J, Jurkovic D, Lissoni AA, et al. A novel approach to predict the likelihood of specific ovarian tumor pathology based on serum CA-125: A multicenter observational study likelihood of ovarian tumor pathology based on serum CA-125. *Cancer epidemiology, biomarkers & prevention*. 2011;20(11):2420-2428.
 119. Wijaya R, Murti K, Hafy Z. Hubungan kadar CA-125 dengan subtype epitel tumor ganas ovarium pada penderita yang dirawat di RSUP Dr. Mohammad Hoesin Palembang tahun 2013-2016. *Majalah Kedokteran Sriwijaya*. 2017;49(4):197-204
 120. Mitra AK. Ovarian cancer metastasis :a unique mechanism of dissemination. *Intech Open*. 2016. Available from:<https://www.intechopen.com/chapters/51874>. Diakses 1 Oktober 2022.
 121. Cheung A, Shah S, Parker J, Soor P, Limbu A, Sheriff M, et al. Non-epithelial ovarian cancers: how much do we really know?. *International Journal of Environmental Research and Public Health*. 2022;19(3):1106.
 122. Salima S, Rachmawati A, Harsono AB, Erfiandi F, Fauzi H, Prasecti H. Ovarian Cancer-Self Assessment: An Innovation for Early Detection and Risk Assessment of Ovarian Cancer. *Asian Pacific Journal of Cancer Prevention*. 2022;23(8), 2643-2647.
 123. King MT, Stockler MR, O'Connell RL, Buizen L, Joly F, Lanceley A, et al. Measuring what matters MOST: validation of the Measure of Ovarian Symptoms and Treatment, a patient-reported outcome measure of symptom burden and impact of chemotherapy in recurrent ovarian cancer. *Quality of Life Research*. 2017;27(1):59-74.
 124. Gaona-Luviano P, Medina-Gaona LA, Magaña-Pérez K. Epidemiology of ovarian cancer. *Chin Clin Oncol*. 2020;9(4):47.
 125. Pitta DDR, Sarian LO, Barreta A, Campos EA, de Angelo Andrade LL, Fachini AMD, et al. Symptoms, CA125 and HE4 for the preoperative prediction of ovarian malignancy in Brazilian women with ovarian masses. *BMC cancer*. 2013;13(1):1-11.
 126. Sarkar S, Pal R, Mahata S, Sahoo PK, Ghosh S, Chatterjee P, et al. Evaluation of numerical rating scale and neuropathic pain symptom inventory pain scores in advanced ovarian carcinoma patients undergoing surgery and first-line chemotherapy. *Journal of Clinical and Translational*

- Research. 2022;8(1): 54.
127. Jayson GC, Kohn EC, Kitchener HC, Ledermann JA. Ovarian cancer. *The Lancet*. 2014;384(9951):1376-1388.
 128. Colombo N, Peiretti M, Castiglione M. Non-epithelial ovarian cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. *Annals of oncology*. 2009;20:iv24-iv26.
 129. Kocoglu H, Pirbudak L, Pence S, Balat O. Cancer pain, pathophysiology, characteristics and syndromes. *European journal of gynaecological oncology*,. 2002;23(6):527-532.
 130. Portenoy RK, Ahmed E. Cancer pain syndromes. *Hematology/Oncology Clinics*. 2018;32(3):371-386.
 131. Kim MK, Kim K, Kim SM, Kim JW, Park NH, Song YS, et al. A hospital-based case-control study of identifying ovarian cancer using symptom index. *Journal of gynecologic oncology*. 2009;20(4):238-242.
 132. Rosen DG, Yang G, Liu G, Mercado-Uribe I, Chang B, Xiao XS, et al. Ovarian cancer: pathology, biology, and disease models. *Frontiers in bioscience: a journal and virtual library*. 2009;14:2089.
 133. Desai JP, Moustarah F. *Peritoneal Metastasis*. Treasure Island (FL): Stat Pearls Publishing. 2022. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK541114/>. Diakses 10 September 2022.
 134. Xin DAN, Yalin TIAN, Li ZHOU, Juan DU, Yalin HE. Longitudinal Change in Symptom Clusters in Patients With Ovarian Cancer. *Journal of Nursing Research*. 2022;30(2):196.
 135. Guenther J, Stiles A, Champion JD. The lived experience of ovarian cancer: A phenomenological approach. *Journal of the american academy of nurse practitioners*. 2012;24(10):595-603
 136. Quan Q, Zhou S, Liu Y, Yin W, Liao Q, Ren S, et al. Relationship between ascites volume and clinical outcomes in epithelial ovarian cancer. *Journal of Obstetrics and Gynaecology Research*. 2021;47(4):1527-1535.
 137. Qian L, Ren J, Liu A, Gao Y, Hao F, Zhao L, et al. MR imaging of epithelial ovarian cancer: a combined model to predict histologic subtypes. *European Radiology*. 2020;30(11):5815-5825.
 138. Shen-Gunther J, Mannel RS. Ascites as a predictor of ovarian malignancy. *Gynecologic oncology*. 2002;87(1): 77-83.
 139. Lengyel E. Ovarian cancer development and metastasis. *The American J of Pathology*. 2010 ; 177(3): 1053–1064.
 140. Rickard BP, Conrad C, Sorrin AJ, Ruhi MK, Reader JC, Huang SA, et al. Malignant ascites in ovarian cancer: cellular, acellular, and biophysical determinants of molecular characteristics and therapy response. *Cancers*. 2021;13(17):4318.
 141. Garima Y, Pratibha S, Priyanka K, Meenakshi G. Correlation Between Preoperative Clinical Diagnosis, Imaging and Histopathology of Adnexal Masses: A Retrospective Study. *Indian Journal of Gynecologic Oncology*. 2013;16(3):1-5.
 142. Shetty J, Saradha A, Pandey D, Bhat R, Kumar P, Bharatnur S. IOTA simple ultrasound rules for triage of adnexal mass: Experience from South

- India. *The Journal of Obstetrics and Gynecology of India*. 2019;69(4):356-362.
143. Gao Y, Zeng S, Xu X, Li H, Yao S, Song K, et al. Deep learning-enabled pelvic ultrasound images for accurate diagnosis of ovarian cancer in China: a retrospective, multicentre, diagnostic study. *The Lancet Digital Health*. 2022;4(3):179-187.
144. Kamal R, Hamed S, Mansour S, Mounir Y, Abdel Sallam S. Ovarian cancer screening—ultrasound; impact on ovarian cancer mortality. *The British journal of radiology*. 2018;91(1090)
145. Hartman CA, Juliato CRT, Sarian LO, Toledo MC, Jales RM, Morais SS, et al. Ultrasound criteria and CA 125 as predictive variables of ovarian cancer in women with adnexal tumors. *Ultrasound in obstetrics & gynecology*. 2012;40(3):360-366
146. Nunes N, Ambler G, Foo X, Naftalin J, Widschwendter M, Jurkovic D. Use of IOTA simple rules for diagnosis of ovarian cancer: meta-analysis. *Ultrasound in Obstetrics & Gynecology*. 2014;44(5):503- 514.
147. Szubert S, Wojtowicz A, Moszynski R, Zywica P, Dyczkowski K, Stachowiak A, et al. External validation of the IOTA ADNEX model performed by two independent gynecologic centers. *Gynecologic Oncology*. 2016;142(3):490-495.
148. de Gauna BR, Rodriguez D, Olartecochea B, Aubá M, Jurado M, Roig MDG, et al. Diagnostic performance of IOTA simple rules for adnexal masses classification: a comparison between two centers with different ovarian cancer prevalence. *European Journal of Obstetrics & Gynecology and Reproductive Biology*. 2015;191:10-14.
149. Khalaf LM, Desoky HH, Seifeldein GS, Salah A, Amine MA, Hussien MT. Sonographic and Doppler predictors of malignancy in ovarian lesions. *Egyptian Journal of Radiology and Nuclear Medicine* 2020;51(1):1-8.
150. Medina-Franco H, Colonna-Márquez LE. Non-epithelial ovarian carcinoma: what is the optimal staging surgery?. *Chinese Clinical Oncology*. 2020;9(4):50-50